title: Anti-metastatics: an overview of drug candidates in current pipelines.
abstract: As the number of novel drugs that have entered the market in oncology has slowed in recent years, there has been a dramatic shift towards new therapeutic approaches. The majority of cancer patients die from metastasis formation, which has prompted the pharmaceutical industry to begin to investigate a new class of agents: anti-metastatics. This review provides an overview of the targets, mechanisms of action, and drug substances currently in the pharma pipeline to inhibit tumor cell migration and metastasis formation.
authors.forename: Anne
authors.initials: A
authors.lastname: Schaap-Nutt
authors.forename: Dane A
authors.initials: DA
authors.lastname: Thyssen
authors.forename: David W
authors.initials: DW
authors.lastname: Drell
authors.affiliation: MetaVi Labs Inc, 16238 Ranch Road 620 North, Suite F-347, Austin, Texas 78717, USA. fentschladen@metavilabs.com.
authors.forename: Frank
authors.initials: F
authors.lastname: Entschladen
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D002465:Cell Movement / Q000187:drug effects; D006801:Humans; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000473:pathology*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents